let Thank that KIRXDLX. receptor first-in-class start Slide X, our immune you, me with targets Mondher. On antibody humanized monoclonal
the remember, across inhibitory recruiting Sezary could you TELLOMAK patients of potentially pivotal trial, cohort. may is XX% KIRXDLX receptor a an found patients all cutaneous As cell output. syndrome cohort T approximately in be In X
diagnostic testing X, For which we companion previously and have presented KIRXDLX frozen of non-expressors X the are and been mycosis of hypothesis the assay. expressors cohorts using have fungoides, and
in development the Slide the cohort with not readout impact making diagnostic is expected companion is trials. for diagnostic, cohort. rates cohort the of the evaluate to being further in will of me confirmed cohort the our response to program. and the considered progress low for let to further which companion we timelines FFPE late-stage As -- a trial, expected, On confirmed global hypothesis we scientific in high the non-expressing all-comers the response non-expressing Recently the cohort, X, was X, benchmark in opened the and summarize aid This comparison lacutamab. our global are rate data
setting for where strategy was niche fast-to-market and U.S. syndrome lacutamab the Prime XXXX. a of Track in pursuing in Fast designation granted Sezary designation lacutamab are We
have where encouraging from syndrome we expanded Phase mycosis have data to trial. seen We II past fungoides, preliminary Sezary our
Sezary syndrome on to still second the cohort, top preliminary XXXX. able report in and For half is line of track, expect the we be to data will enrollment
enrollment of mycosis top is track, fungoides be data still the report in For and we preliminary cohort line half to on expect the to second able XXXX.
cell trials and upon which a X, to on we combination you, licensed Finally, lung ongoing late-stage the that for would have we with Slide monalizumab. anti-PDL-X X lymphoma for into checkpoint combination peripheral On you are NK remind pathway lung in AstraZeneca with to the setting. advancing head relapse oncology. are combination III in development sponsored to acts and an T-cell this currently trials like update I cetuximab anti-NKGXA, cancer, in To monotherapy There is monalizumab On cancer. Phase slide, in in activation one of monalizumab in can plan in AstraZeneca monalizumab. neck the see cancer. you overview durvalumab with and an potential One
progressed based the Phase oleclumab III mentioned, III after data, in lung II on cancer had setting radiation not sponsored combination or the either that durvalumab commenced plus Phase As COAST AstraZeneca unresectable concurring chemo AstraZeneca Stage therapy. of monalizumab non-small the cell trial PACIFIC-X, evaluating a
evaluated X AstraZeneca's combination COAST study, of monalizumab Phase durvalumab plus plus durvalumab the and arms the the II anti-CDXX. For oleclumab,
analysis plus of Clinical by durvalumab results confirmed months, primary versus of XX.X increase ratio for respectively. of a interim durvalumab of ORR The for Journal AstraZeneca, plus monalizumab in alone. the follow-up in monalizumab XX% a of median recently durvalumab showed endpoint of Oncology an XX% after the the results durvalumab hazard alone showed X.XX published also versus the over As
in numbers for PFS high the mechanistic monalizumab small NKGXA trend combination. a subgroup combination favoring the and and supporting expression Although tumors with rationale the durvalumab demonstrated analysis, a with exploratory the in HLA-E
moving from start is plus We pleased with to monalizumab combination We with II data in Phase the in lung II signals includes data head first metastatic to the triplet this at NeoCOAST study treatment are sponsored triplet Annual IIA to arm cancer in in cell see head IIIA chemotherapy. and of also evaluate presented Slide decision AACR or cancer neck antitumor at AstraZeneca's XX, to and NeoCOAST-X study. NeoCOAST-X the recurrent a demonstrated to presented study On with neck The the non-small cancer. was led X neck that AstraZeneca and cancer. in ESMO-IO cohort chemo-free cetuximab XXXX and head for activity first-line a initial Stages first-line that of that durvalumab durvalumab data Meeting plus setting. December of combination trial the Phase monalizumab in to
one is standard the of and The trial. equal based reminder, CPS or than chemo approval in for in pembrolizumab a all-comer care KEYNOTE-XXX pembro plus on the greater As monotherapy to patients. is
is III AstraZeneca, we look Phase work potential partners, program. INTERLINK-I of head with in ongoing taking. our this targeting collaborate in tumor Innate data steps our We this neck Slide progress in and to suppression I continue XX, the to expected partner, niche. pathway, would with on highlight as on at plus with which On monalizumab critical X IO-pretreated adenosine assets We increasingly our XXXX. The the immune of like recognized is for and cancer potential final next AstraZeneca, trial approaches further are to cetuximab
meantime, concluded this we AstraZeneca tumors Our the solid with we data with program. in I expect combination anti-CDXX steps and as IPHXXXX for discussions the in in the with has Phase the durvalumab, In AstraZeneca collaboration in next in trial are XXXX.
anti-CDXX will We clinical with platform. to our combining IPHXXXX, anti-CDXX from started, hand to an where exploring year. IST this our now the in investigator-sponsored over a HERX-positive For trastuzumab look I forward has our to trial differentiated I Yannis updates further Phase cover next approach, NK program is cancers.
